GlaxoSmithKline (NYSE:GSK) dermatology and skin subsidiary Stiefel has submitted to regulators a new drug application for tazarotene foam, an acne skin care treatment product. If approved by the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback